Efficacy of Benfluorex in Combination With Sulfonylurea in Type 2 Diabetic Patients: An 18-Week, Randomized, Double-Blind Study

Diabetes Care- United States

doi 10.2337/diacare.29.03.06.dc05-1439

Full Text

Abstract

Available in

Date

Authors

Publisher

American Diabetes Association

Related search

A One-Year Multicentre, International, Randomised, Double-Blind Study With Comparison of Benfluorex Versus an Oral Anti-Diabetic in Combination With Sulfonylurea Administered Orally for the Treatment of Type Two Diabetes

2013English

Efficacy of Fixed-Dose Amlodipine and Losartan Combination Compared With Amlodipine Monotherapy in Stage 2 Hypertension: A Randomized, Double Blind, Multicenter Study

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2011English

A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Hydroxychloroquine in Patients With Type 2 Diabetes Mellitus

Global Journal of Endocrinological Metabolism
2018English

Propolis Supplementation Improves Glycemic and Antioxidant Status in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study

Complementary Therapies in Medicine
Alternative MedicineManual TherapySpecialized NursingAdvancedComplementary
2019English

Anti-Hyperglycemic and Anti-Hyperlipidemic Effects of Lupinus Albus in Type 2 Diabetic Patients: A Randomized Double-Blind, Placebo-Controlled Clinical Trial

International Journal of Pharmacology
Pharmacology
2016English

Rosiglitazone in Combination With Glimepiride Plus Metformin in Type 2 Diabetic Patients

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2002English

Transglucosidase Improves the Bowel Movements in Type 2 Diabetes Mellitus Patients: A Preliminary Randomized Double-Blind, Placebo-Controlled Study

United European Gastroenterology Journal
OncologyGastroenterology
2017English

The Effect of Aggressive Versus Standard Lipid Lowering by Atorvastatin on Diabetic Dyslipidemia: The DALI Study: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients With Type 2 Diabetes and Diabetic Dyslipidemia

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2001English

The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy